Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, ...

Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or ...

Incyte (INCY) stock dropped 0.78% to $98.22 as Japan approved Minjuvi for relapsed DLBCL treatment, marking the drug's second ...

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a ...

Susan Bal, MD, associate professor at the University of Alabama in Birmingham, discusses the final results from an ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 ...

High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and ...

Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death1 People with relapsed ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated. To ...

Dose escalation continues in the U.S. Phase 1 clinical trial; the maximum tolerated dose has not been determined.